Citi Sticks to Its Hold Rating for Arvinas Holding Company (ARVN)

In a report released today, Yigal Nochomovitz from Citi maintained a Hold rating on Arvinas Holding Company, with a price target of $10.00. The company’s shares closed yesterday at $9.62.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Nochomovitz is a 4-star analyst with an average return of 8.4% and a 44.47% success rate. Nochomovitz covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, ProKidney, and Summit Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Arvinas Holding Company with a $19.86 average price target, implying a 106.44% upside from current levels. In a report released yesterday, Bank of America Securities also reiterated a Hold rating on the stock with a $12.00 price target.

Based on Arvinas Holding Company’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $22.4 million and a GAAP net loss of $61.2 million. In comparison, last year the company earned a revenue of $76.5 million and had a GAAP net loss of $35.2 million

Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ARVN in relation to earlier this year. Last month, Briggs Morrison, a Director at ARVN bought 30,000.00 shares for a total of $226,800.00.